IBA – ACQUISITION OF OWN SHARES

GlobeNewswire
04-08

Immediate Release – April 7th, 2025

Louvain-la-Neuve, Belgium, April 7th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025.

Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th, 2025, to cover the company’s obligations under long-term incentive plans for management and certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 43,000 IBA shares on Euronext Brussels in the period from April 1st, 2025, up to and including April 7th, 2025, as follows:

Trade date Shares purchased Average price Min price Max price Buyback amount
01-04-25 6.000 11,05 € 10,88 € 11,10 € 66.290,40 €
02-04-25 8.000 10,83 € 10,70 € 11,10 € 86.668,00 €
03-04-25 9.000 10,57 € 10,50 € 10,72 € 95.166,90 €
04-04-25 10.000 10,17 € 9,89 € 10,40 € 101.749,00 €
07-04-25 10.000 10,08 € 9,40 € 10,52 € 100.801,00 €
TOTAL 43.000 10,48 € 9,40 € 11,10 € 450.675,30 €

The total number of shares purchased under this program therefore amounts to 136,017 since this is the second week of execution. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SRL) is the following :

    Shares Voting rights
IBA Investments SRL 51.973 103.946
IBA SA   449.596 516.019
Total - Treasury shares 501.569 619.965
Total - Issued shares 30.282.218 40.514.366
Treasury shares in % 1,66% 1,53%

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

Contact person

IBA
Thomas Pevenage,
Investor Relations
investorrelations@iba-group.com


Attachment

  • 250407-Buyback-IBA-EN

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10